Tetraphase Pharmaceuticals President & CEO Guy Macdonald to Present at 2011 BIO International Convention

WATERTOWN, Mass.--(BUSINESS WIRE)-- Tetraphase Pharmaceuticals, Inc., a clinical-stage life science company developing a portfolio of potent new antibiotics designed to be effective against dangerous, drug-resistant bacteria, including multidrug-resistant (MDR) gram-negative pathogens, today announced that the company will present at the 2011 BIO International Convention being held June 27 to 30 in Washington, D.C. at the Walter E. Washington Convention Center. Tetraphase President and Chief Executive Officer Guy Macdonald will participate in a panel entitled “Financing Beyond the Lead Compound: Attracting Funding for Multiproduct Platforms,” which will take place on Tuesday, June 28, from 10:00 a.m. until 11:30 a.m.

About Tetraphase Pharmaceuticals Inc.

Tetraphase Pharmaceuticals is a clinical-stage biopharmaceutical company utilizing its breakthrough synthetic chemistry technology platform to discover and develop next-generation tetracycline antibiotics that address unmet needs for serious infections such as drug resistance and Gram-negative infections. The company has developed an emerging pipeline of potent novel antibiotics that provide a portfolio of intravenous and oral drug candidates with the potential to treat a wide range of infections, including broad-spectrum and selective-spectrum infections. To learn more about Tetraphase, please visit http://www.tphase.com.



CONTACT:

Sam Brown Inc.
Mike Beyer, 773-463-4211
[email protected]

KEYWORDS:   United States  North America  District of Columbia  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.